Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index; 10 of the 28 sources its claims cite were checked for support.
Abstract
BACKGROUND AND OBJECTIVE: Gene therapies for sickle cell disease (SCD) may offer meaningful benefits for patients and society. This study evaluated the cost-effectiveness of lovotibeglogene autotemcel (lovo-cel), a one-time gene therapy administered via autologous hematopoietic stem cell transplantation, compared with common care for patients in the United States (US) with SCD aged ≥ 12 years with ≥ 4 vaso-occlusive events (VOEs) in the past 24 months. METHODS: We developed a patient-level simulation model accounting for lovo-cel and SCD-related events, complications, and mortality over a lifetime time horizon. The pivotal phase 1/2 HGB-206 clinical trial (NCT02140554) served as the basis for lovo-cel efficacy and safety. Cost, quality-of-life, and other clinical data were sourced from HGB-206 data and the literature. Analyses were conducted from US societal and third-party payer perspectives. Uncertainty was assessed through probabilistic sensitivity analysis and extensive scenario analyses. RESULTS: Patients treated with lovo-cel were predicted to survive 23.84 years longer on average (standard deviation [SD], 12.80) versus common care (life expectancy, 62.24 versus 38.40 years), with associated discounted patient quality-adjusted life-year (QALY) gains of 10.20 (SD, 4.10) and direct costs avoided of $1,329,201 (SD, $1,346,446) per patient. Predicted societal benefits included discounted caregiver QALY losses avoided of 1.19 (SD, 1.38) and indirect costs avoided of $540,416 (SD, $262,353) per patient. Including lovo-cel costs ($3,282,009 [SD, $29,690] per patient) resulted in incremental cost-effectiveness ratios of $191,519 and $124,051 per QALY gained from third-party payer and societal perspectives, respectively. In scenario analyses, the predicted cost-effectiveness of lovo-cel also was sensitive to baseline age and VOE frequency and to the proportion of patients achieving and maintaining complete resolution of VOEs. CONCLUSIONS: Our analysis of lovo-cel gene therapy compared with common care for patients in the US with SCD with recurrent VOEs estimated meaningful improvements in survival, quality of life, and other clinical outcomes accompanied by increased overall costs for the health care system and for broader society. The predicted economic value of lovo-cel gene therapy was influenced by uncertainty in long-term clinical effects and by positive spillover effects on patient productivity and caregiver burden.
Overview
CoChat Summary
## TL;DR
This study modeled the lifetime cost-effectiveness of lovotibeglogene autotemcel (lovo-cel) versus common care for US patients aged ≥12 years with sickle cell disease and ≥4 vaso-occlusive events in the prior 24 months. It found large predicted survival and quality-of-life gains, but at high upfront cost, with incremental cost-effectiveness ratios of $191,519/QALY from a third-party payer perspective and $124,051/QALY from a societal perspective.
## Key findings
- In the base case, lovo-cel was predicted to increase life expectancy by 23.84 years on average, with survival of 62.24 versus 38.40 years for common care.
- Discounted QALY gains were 10.20 per patient, and direct costs avoided were $1,329,201 per patient.
- From the societal perspective, lovo-cel was predicted to avoid 1.19 caregiver QALYs lost and $540,416 in indirect costs per patient.
- Total lovo-cel-related costs were estimated at $3,282,009 per patient; resulting ICERs were $191,519/QALY (third-party payer) and $124,051/QALY (societal).
- At a willingness-to-pay threshold of $150,000/QALY, net monetary benefit was negative from the third-party payer perspective (−$423,347) and positive from the societal perspective ($295,445).
- Scenario analyses showed results were most sensitive to baseline age, VOE frequency, and the proportion of patients achieving and maintaining complete VOE resolution (VOE-CR).
## Methods
- Patient-level simulation cost-effectiveness model with a lifetime horizon, comparing each simulated patient twice: once with common care and once with lovo-cel.
- Target population matched HGB-206 TPVOE criteria: age ≥12 years with ≥4 VOEs in the prior 24 months; modeled cohort size was 2,500 patients.
- Efficacy/safety came primarily from the pivotal phase 1/2 HGB-206 trial; costs, utilities, and other parameters came from HGB-206 data and the literature; analyses used US third-party payer and societal perspectives.
- Main analyses included base-case ICERs per QALY, plus probabilistic sensitivity analysis, targeted scenario analyses, and one-way sensitivity analyses.
## Limitations
- The paper states that the target population was aligned with the HGB-206 trial, but real-world patients may differ in baseline age, SCD severity, and comorbidity profile.
- It states that longer-term data are needed to confirm lifetime impact, because HGB-206 follow-up extends only to 61 months after transplantation.
- It states that results are sensitive to uncertainty in achieving and maintaining VOE-CR and to simplifying assumptions in the common care arm; this is evident from the text’s reliance on constant hydroxyurea/transfusion use and exclusion of common-care-specific adverse events such as iron overload.
- Evident from the model description: the analysis assumes benefits persist for life in the base case and does not model fertility impacts of SCD or myeloablative conditioning, except fertility preservation costs.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
10 Valid · 0 Not valid · 9 Not checked · 67 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The model leveraged educational pathways research [63] to project that achieving VOE-CR would support educational and work productivity gains, resulting in higher annual earnings depending on the age at treatment.”
§ Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States > Methods > Model Parameters
What the sources say
- Partly supportedcites [63] Graf M, Tuly R, Gallagher M, Sullivan J, Jena AB. Value of a cure for sickle cell disease in reducing economic disparities. Am J Hematol. 2022;97(8):E289–91. sourceExperimental — accuracy not yet measured
In the paper’s main text (page unavailable), the model links a cure for sickle cell disease to greater educational opportunity and productivity, and projects higher annual earnings that differ by whether treatment occurs before or during/after high school. It models a generic cure, however, not VOE-CR achieved with lovo-cel; that treatment-specific application is not established by this source. (LLM, conf=0.87)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Emerging disease-modifying therapies for SCD (l-glutamine, crizanlizumab, and voxelotor) were not considered as comparators, as their use remains limited in the US [36].”
§ Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States > Methods > Modeling Approach
What the sources say
- Partly supportedcites [36] Migotsky M, Beestrum M, Badawy SM. Recent advances in sickle-cell disease therapies: a review of voxelotor, crizanlizumab, and l-glutamine. Pharmacy (Basel). 2022;10(5):123. sourceExperimental — accuracy not yet measured
The Discussion describes cost, insurance approval, and transportation as barriers to using all three therapies. Section 3.4 reports low uptake or continuation in some centers, but the paper does not establish that their use is limited across the US. The decision not to include them as comparators belongs to the citing authors, not this source. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Those achieving VOE-CR with lovo-cel after age 15 years would have annual earnings equal to 78% of race-adjusted general population earnings [63].”
§ Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States > Methods > Model Parameters
What the sources say
- Partly supportedcites [63] Graf M, Tuly R, Gallagher M, Sullivan J, Jena AB. Value of a cure for sickle cell disease in reducing economic disparities. Am J Hematol. 2022;97(8):E289–91. sourceExperimental — accuracy not yet measured
The paper’s model-results passage (page unavailable) projects annual earnings 22% below a healthy comparison group for people cured during or after high school, equivalent to 78%. It does not identify lovo-cel or VOE-CR, specify an age-15 cutoff, or describe that 78% figure as a comparison with race-adjusted general-population earnings. (LLM, conf=0.87)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Specifically, patients achieving VOE-CR with lovo-cel prior to age 15 years (i.e., early enough to affect secondary educational outcomes) would have annual earnings equal to 92% (versus 56% for SCD overall) of race-adjusted general population earnings [63].”
§ Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States > Methods > Model Parameters
What the sources say
- Partly supportedcites [63] Graf M, Tuly R, Gallagher M, Sullivan J, Jena AB. Value of a cure for sickle cell disease in reducing economic disparities. Am J Hematol. 2022;97(8):E289–91. sourceExperimental — accuracy not yet measured
The paper’s main text (page unavailable) projects that people cured before high school would earn 8% less annually than a healthy comparison group—equivalent to 92%. It reports that people with SCD earn 42%–46% less than matched controls, a range that includes the cited 56%. The model concerns a generic cure before high school; it does not establish this projection specifically for lovo-cel, VOE-CR, or treatment before age 15. (LLM, conf=0.88)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and direct costs avoided of $1,329,201 (SD, $1,346,446) per patient.”
§ Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
45 more claims
Create a free account to see all 86 claims and to verify the 3 references still open.
- Probably not a substantial claim. 14
- It may state two separate claims as one. 23
Citations
Cites
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320 · cited 2×
“For patients achieving a partial resolution of VOEs (i.e., 100% reduction), a more limited indirect treatment effect was modeled, informed by litera-ture-based relationships (Tables S7–S10 in the Supplementary Information).”
Decision Modelling For Health Economic Evaluation
Briggs, A., Claxton, K., & Sculpher, M. (2006) · doi:10.1093/oso/9780198526629.001.0001 · Cited by 3,153
Sanders, G. D., Neumann, P. J., Basu, A., Brock, D. W., Feeny, D., Krahn, M., Kuntz, K. M., Meltzer, D. O., Owens, D. K., Prosser, L. A., et al. (2016) · JAMA · doi:10.1001/jama.2016.12195 · Cited by 3,069 · cited 6×
“All VOE efficacy outcomes reflect HGB-206 TPVOE Group C data after central adjudi-cation of clinician-identified VOEs.”
InfluentialPain in Sickle Cell Disease: Rates and Risk Factors
Platt, O. S., Thorington, B. D., Brambilla, D. J., Milner, P. F., Rosse, W. F., Vichinsky, E., & Kinney, T. R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107043250103 · Cited by 1,546 · cited 3×
“…the magnitude of risk reductions associated with VOE-CR was assumed to decline with increasing age of treatment (95% for patients aged 12–17 years, 85% for patients aged 18–30 years, and 70% for patients aged > 30 years), acknowledging that lovo-cel will not reverse existing vascular damage.”
Population Estimates of Sickle Cell Disease in the U.S.
Hassell, K. L. (2010) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2009.12.022 · Cited by 1,211 · cited 1×
“States (US) today is estimated at 52.6 years [7, 8], although for those with hemoglobin SS (HbSS) or Sβ 0 -thalassemia (HbSβ 0 ) genotypes, disease severity is much greater and life expectancy estimates are closer to 40 years [8, 9].”
InfluentialBriggs, A. H., Weinstein, M. C., Fenwick, E. A. L., Karnon, J., Sculpher, M. J., & Paltiel, A. D. (2012) · Value in Health · doi:10.1016/j.jval.2012.04.014 · Cited by 823 · cited 2×
“Probability distributions for parameters that were varied in the PSA were selected in accordance with best practices [71, 72] using evidence-based uncertainty estimates where available and reasonable assumptions otherwise (see Table S15 in the Supplementary Information for detailed uncertainty…”
Outcome of Sickle Cell Anemia: A 4-Decade Observational Study of 1056 Patients
Powars, D. R., Chan, L. S., Hiti, A., Ramicone, E., & Johnson, C. (2005) · Medicine · doi:10.1097/01.md.0000189089.45003.52 · Cited by 558 · cited 1×
“The improvement in patient-reported HRQOL observed in the trial was incorporated into the model as a lovo-cel-specific utility gain estimated from the change from baseline in EQ-5D-3L utility values observed in the HGB-206 trial (Table 1 and Table S5 in the Supplementary Information).”
Lakdawalla, D. N., Doshi, J. A., Garrison, L. P., Phelps, C. E., Basu, A., & Danzon, P. M. (2018) · Value in Health · doi:10.1016/j.jval.2017.12.007 · Cited by 540 · cited 2×
“…considered co-base-case analyses from both a US third-party payer perspective (including patient health outcomes and direct medical costs only) and a US societal perspective (including caregiver quality-of-life impacts and indirect costs related to productivity loss and unpaid caregiving) [37–39].”
Caro, J. J., Briggs, A. H., Siebert, U., & Kuntz, K. M. (2012) · Medical Decision Making · doi:10.1177/0272989x12454577 · Cited by 520
United States Life Tables, 2019.
Arias, E., & Xu, J. (2022) · PubMed · Cited by 479
Kavanagh, P. L., Fasipe, T. A., & Wun, T. (2022) · JAMA · doi:10.1001/jama.2022.10233 · Cited by 478
Eddy, D. M., Hollingworth, W., Caro, J. J., Tsevat, J., McDonald, K. M., & Wong, J. B. (2012) · Value in Health · doi:10.1016/j.jval.2012.04.012 · Cited by 466 · cited 1×
“Good practice guidelines for cost-effectiveness model validation emphasize face validity (of the modeling approach and data source), internal validity (of the model programming and predicted outcomes), and external validity (compared with other published studies) [32, 74].”
Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease
Kanter, J., Walters, M. C., Krishnamurti, L., Mapara, M. Y., Kwiatkowski, J. L., Rifkin-Zenenberg, S., Aygun, B., Kasow, K. A., Pierciey, F. J., Bonner, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2117175 · Cited by 442 · cited 4×
“B a s e ca s e”
InfluentialLubeck, D., Agodoa, I., Bhakta, N., Danese, M., Pappu, K., Howard, R., Gleeson, M., Halperin, M., & Lanzkron, S. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.15374 · Cited by 336 · cited 1×
“Sickle cell disease is characterized by frequent and debilitating vaso-occlusive events (VOEs) (e.g., pain crises), stroke, and multisystem organ damage and organ infarction [2], leading to a lifespan cut short by several decades [3, 4].”
AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users
Vemer, P., Corro Ramos, I., van Voorn, G. A. K., Al, M. J., & Feenstra, T. L. (2016) · PharmacoEconomics · doi:10.1007/s40273-015-0327-2 · Cited by 331 · cited 1×
“Good practice guidelines for cost-effectiveness model validation emphasize face validity (of the modeling approach and data source), internal validity (of the model programming and predicted outcomes), and external validity (compared with other published studies) [32, 74].”
Factors associated with survival in a contemporary adult sickle cell disease cohort
Elmariah, H., Garrett, M. E., De Castro, L. M., Jonassaint, J. C., Ataga, K. I., Eckman, J. R., Ashley‐Koch, A. E., & Telen, M. J. (2014) · American Journal of Hematology · doi:10.1002/ajh.23683 · Cited by 300
Conceptualizing a Model: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2
Roberts, M., Russell, L. B., Paltiel, A. D., Chambers, M., McEwan, P., & Krahn, M. (2012) · Value in Health · doi:10.1016/j.jval.2012.06.016 · Cited by 241
Karnon, J., Stahl, J., Brennan, A., Caro, J. J., Mar, J., & Möller, J. (2012) · Value in Health · doi:10.1016/j.jval.2012.04.013 · Cited by 240
Naik, R. P., Streiff, M. B., Haywood, C., Nelson, J. A., & Lanzkron, S. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.12.016 · Cited by 190 · cited 1×
“…and complications in the selected landmark SCD cohort, and to avoid potential double-counting across the range of risk factors for SCD mortality [44, 49, 51–55], we modeled additional increases in mortality risks associated only with a hospitalized VOC [52] and with multiple end-organ…”
Management of sickle cell disease from childhood through adulthood
Kanter, J., & Kruse-Jarres, R. (2013) · Blood Reviews · doi:10.1016/j.blre.2013.09.001 · Cited by 182 · cited 2×
“Sickle cell disease is characterized by frequent and debilitating vaso-occlusive events (VOEs) (e.g., pain crises), stroke, and multisystem organ damage and organ infarction [2], leading to a lifespan cut short by several decades [3, 4].”
Dampier, C., Lieff, S., LeBeau, P., Rhee, S., McMurray, M., Rogers, Z., Smith‐Whitley, K., & Wang, W. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22497 · Cited by 168 · cited 1×
“These events and complications result in broad impacts to quality of life, social functioning, and attainment of personal, educational, and financial goals [5, 6].”
Dampier, C., LeBeau, P., Rhee, S., Lieff, S., Kesler, K., Ballas, S., Rogers, Z., Wang, W., & the Comprehensive Sickle Cell Centers (CSCC) Clinical Trial Consortium (CTC) Site Investigators (2011) · American Journal of Hematology · doi:10.1002/ajh.21905 · Cited by 153
American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation
Kanter, J., Liem, R. I., Bernaudin, F., Bolaños‐Meade, J., Fitzhugh, C. D., Hankins, J. S., Murad, M. H., Panepinto, J. A., Rondelli, D., Shenoy, S. S., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004394c · Cited by 152 · cited 1×
“For the limited group of individuals with a suitable human leukocyte antigen (HLA)–matched sibling donor [13], allogeneic hematopoietic stem cell transplantation (HSCT) offers a potential cure [14].”
Darbari, D. S., Wang, Z., Kwak, M., Hildesheim, M. E., Nichols, J., Allen, D. T., Seamon, C. A., Peters-Lawrence, M. H., Conrey, A. K., Hall, M. K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079923 · Cited by 138 · cited 1×
“…complications in the selected landmark SCD cohort, and to avoid potential double-counting across the range of risk factors for SCD mortality [44, 49, 51–55], we modeled additional increases in mortality risks associated only with a hospitalized VOC [52] and with multiple end-organ involvement [55].”
Maitra, P., Caughey, M., Robinson, L., Desai, P. C., Jones, S., Nouraie, M., Gladwin, M. T., Hinderliter, A., Cai, J., & Ataga, K. I. (2017) · Haematologica · doi:10.3324/haematol.2016.153791 · Cited by 137 · cited 3×
“…complications in the selected landmark SCD cohort, and to avoid potential double-counting across the range of risk factors for SCD mortality [44, 49, 51–55], we modeled additional increases in mortality risks associated only with a hospitalized VOC [52] and with multiple end-organ involvement…”
InfluentialBrunson, A., Lei, A., Rosenberg, A. S., White, R. H., Keegan, T., & Wun, T. (2017) · British Journal of Haematology · doi:10.1111/bjh.14655 · Cited by 129
Lakdawalla, D. N., & Phelps, C. E. (2021) · Value in Health · doi:10.1016/j.jval.2020.10.003 · Cited by 120
Pecker, L. H., & Lanzkron, S. (2021) · Annals of Internal Medicine · doi:10.7326/aitc202101190 · Cited by 112
Health Years in Total: A New Health Objective Function for Cost-Effectiveness Analysis
Basu, A., Carlson, J., & Veenstra, D. (2020) · Value in Health · doi:10.1016/j.jval.2019.10.014 · Cited by 102 · cited 1×
“We also estimated the equal value life-year (evLY) and health years in total (HYT) outcomes as alternatives to the QALY outcome [66, 67].”
Jiao, B., JOHNSON, K., Ramsey, S. D., Bender, M. A., Devine, B., & Basu, A. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009202 · Cited by 96 · cited 1×
“States (US) today is estimated at 52.6 years [7, 8], although for those with hemoglobin SS (HbSS) or Sβ 0 -thalassemia (HbSβ 0 ) genotypes, disease severity is much greater and life expectancy estimates are closer to 40 years [8, 9].”
InfluentialFresh from the biotech pipeline: fewer approvals, but biologics gain share
Senior, M. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01630-6 · Cited by 70 · cited 1×
“…donor, its approval in the US could result in expanded access to potentially curative treatments for SCD. Cell and gene therapies, such as lovo-cel, constitute both an increasing percentage of the total drug development pipe-line as well as an increasing share of new drug approvals [18, 19].”
Chaturvedi, S., Ghafuri, D. L., Jordan, N., Kassim, A. A., Rodeghier, M., & DeBaun, M. R. (2018) · American Journal of Hematology · doi:10.1002/ajh.25202 · Cited by 60 · cited 2×
“The improvement in patient-reported HRQOL observed in the trial was incorporated into the model as a lovo-cel-specific utility gain estimated from the change from baseline in EQ-5D-3L utility values observed in the HGB-206 trial (Table 1 and Table S5 in the Supplementary Information).”
Sickle cell disease: time for a closer look at treatment options?
Sheth, S., Licursi, M., & Bhatia, M. (2013) · British Journal of Haematology · doi:10.1111/bjh.12413 · Cited by 57 · cited 2×
“For the limited group of individuals with a suitable human leukocyte antigen (HLA)–matched sibling donor [13], allogeneic hematopoietic stem cell transplantation (HSCT) offers a potential cure [14].”
McClish, D. K., Smith, W. R., Levenson, J. L., Aisiku, I. P., Roberts, J. D., Roseff, S. D., & Bovbjerg, V. E. (2017) · BioMed Research International · doi:10.1155/2017/4070547 · Cited by 55
A Budget Impact Analysis of Gene Therapy for Sickle Cell Disease: The Medicaid Perspective
DeMartino, P. C., Haag, M. B., Hersh, A. R., Caughey, A. B., & Roth, J. A. (2021) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2020.7140 · Cited by 48
Young, C. M., Quinn, C., & Trusheim, M. R. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.09.001 · Cited by 47 · cited 1×
“…donor, its approval in the US could result in expanded access to potentially curative treatments for SCD. Cell and gene therapies, such as lovo-cel, constitute both an increasing percentage of the total drug development pipe-line as well as an increasing share of new drug approvals [18, 19].”
Shah, N., Bhor, M., Latrémouille-Viau, D., Sharma, V. K., Puckrein, G. A., Gagnon‐Sanschagrin, P., Khare, A., Singh, M. K., Serra, E., Davidson, M., et al. (2020) · Journal of Medical Economics · doi:10.1080/13696998.2020.1813144 · Cited by 42 · cited 1×
“Common care treatment use (HU, chronic RBC transfusions, or neither) at baseline was derived from published literature [40] and clinical opinion.”
Self-citationGarrison, L. P., Jiao, B., & Dabbous, O. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.27.5.674 · Cited by 41
Goshua, G., Calhoun, C., Ito, S., James, L. P., Luviano, A., Krishnamurti, L., & Pandya, A. (2023) · Annals of Internal Medicine · doi:10.7326/m22-3272 · Cited by 41
Cost-effectiveness of a hypothetical cell or gene therapy cure for sickle cell disease
Salcedo, J. D., Bulovic, J., & Young, C. M. (2021) · Scientific Reports · doi:10.1038/s41598-021-90405-1 · Cited by 35
Migotsky, M., Beestrum, M., & Badawy, S. M. (2022) · Pharmacy · doi:10.3390/pharmacy10050123 · Cited by 33 · cited 1×
“Emerging disease-modifying therapies for SCD ( l -glutamine, crizan-lizumab, and voxelotor) were not considered as comparators, as their use remains limited in the US [36].”
Towse, A., & Fenwick, E. (2019) · Value in Health · doi:10.1016/j.jval.2019.03.013 · Cited by 32 · cited 1×
“Good practice guidelines for cost-effectiveness model validation emphasize face validity (of the modeling approach and data source), internal validity (of the model programming and predicted outcomes), and external validity (compared with other published studies) [32, 74].”
An Alternative Measure of Health for Value Assessment: The Equal Value Life-Year
Campbell, J. D., Whittington, M. D., & Pearson, S. D. (2023) · PharmacoEconomics · doi:10.1007/s40273-023-01302-6 · Cited by 30 · cited 1×
“We also estimated the equal value life-year (evLY) and health years in total (HYT) outcomes as alternatives to the QALY outcome [66, 67].”
Basu, A., Winn, A. N., Johnson, K. M., Jiao, B., Devine, B., Hankins, J. S., Arnold, S. D., Bender, M. A., & Ramsey, S. D. (2024) · Annals of Internal Medicine · doi:10.7326/m23-1520 · Cited by 28
Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations
Garrison, L. P., Pezalla, E., Towse, A., Yang, H., Faust, E., Wu, E. Q., Li, N., Sawyer, E. K., & Recht, M. (2021) · Value in Health · doi:10.1016/j.jval.2021.05.008 · Cited by 27 · cited 1×
“The approval of gene and other advanced therapies with high one-time acquisition costs and uncertain long-term benefits has increased interest in alternative payment models and performance-based managed entry agreements [75–78].”
Campbell, A., Cong, Z., Agodoa, I., et al. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.20009 · Cited by 26
Estimating the Financial Impact of Gene Therapy in the U.S.
Wong, C. H., Li, D., Wang, N., B, J. G. A., Conti, R. M., & Lo, A. W. (2021) · National Bureau of Economic Research · doi:10.3386/w28628 · Cited by 22
Manwani, D. G., Burnett, A. L. “., Paulose, J., Yen, G., Burton, T. M., Anderson, A. J., Wang, S., Lee, S., & Saraf, S. L. (2022) · eJHaem · doi:10.1002/jha2.575 · Cited by 22 · cited 1×
“Data on patients’ acute event histories and existing chronic complications at model entry were obtained from a combination of aggregated HGB-206 TPVOE baseline data (Table S2 in the Supplementary Information) and studies identified in the SCD clinical literature [41–45].”
Qiu, T., Pochopień, M., Liang, S., Saal, G., Paterak, E., Janik, J., & Toumi, M. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.773629 · Cited by 20 · cited 2×
“These technologies hold great promise for patients, their care networks, and broader society, but they are also prompting important discussions on value, access, and affordability [20, 21].”
Kansal, A. R., Reifsnider, O. S., Brand, S. B., Hawkins, N., Coughlan, A., Li, S., Cragin, L. S., Paramore, C., Dietz, A. C., & Caro, J. J. (2021) · Journal of Market Access & Health Policy · doi:10.1080/20016689.2021.1922028 · Cited by 19
Self-citationThe Use of Cost-Effectiveness Analysis in Sickle Cell Disease: A Critical Review of the Literature
Jiao, B., Basu, A., Roth, J. A., Bender, M., Rovira, I. I., Clemons, T. E., Quach, D., Ramsey, S. D., & Devine, B. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01072-z · Cited by 19 · cited 1×
“This study contributes to the growing literature on the cost-effectiveness of advanced treatments for SCD, offering synergies and advantages relative to other recent work [79].”
Health state utilities associated with treatment for transfusion-dependent β-thalassemia
Matza, L. S., Paramore, L. C., Stewart, K. D., Karn, H., Jobanputra, M., & Dietz, A. C. (2019) · The European Journal of Health Economics · doi:10.1007/s10198-019-01136-0 · Cited by 18 · cited 1×
“Data sources and parameter values for patient and caregiver utilities are presented in Table S14 in the Supplementary Information.”
Kanter, J., Thompson, A. A., Kwiatkowski, J. L., Parikh, S., Mapara, M., Rifkin-Zenenberg, S., Aygun, B., Kasow, K. A., Gupta, A. O., Zhang, L., et al. (2023) · Blood · doi:10.1182/blood-2023-174229 · Cited by 15
Self-citationGallagher, M. E., Chawla, A., Brady, B. L., & Badawy, S. M. (2022) · Journal of Medical Economics · doi:10.1080/13696998.2022.2133824 · Cited by 13 · cited 1×
“In alignment with literature showing that annual direct costs for patients with SCD are highest between ages 18 and 30 years [61, 62], we applied age-specific multipliers to the costs for all acute events and chronic complications.”
Self-citationUnited States Life Tables, 2019
Arias, E., & Xu, J. (2022) · doi:10.15620/cdc:113096 · Cited by 11
Health State Utilities for Sickle Cell Disease: A Catalog Prepared From a Systematic Review
Jiao, B., Basu, A., Ramsey, S. D., Roth, J. A., Bender, M. A., Quach, D., & Devine, B. (2021) · Value in Health · doi:10.1016/j.jval.2021.08.002 · Cited by 8
JOHNSON, K., Jiao, B., Bender, M. A., Ramsey, S. D., Devine, B., & Basu, A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267448 · Cited by 6 · cited 1×
“This rationale is similarly reflected in other recent cost-effectiveness modeling frameworks for gene therapies in SCD [22, 23, 29].”
Winn, A. N., Basu, A., & Ramsey, S. D. (2023) · PharmacoEconomics - Open · doi:10.1007/s41669-023-00390-6 · Cited by 4 · cited 3×
“The breadth of SCD-related events and complications included in our analysis is comparable to other comprehensive analyses of gene therapies [22–25, 29] , and there is Our analysis, the MEASURE analysis [29], and the ICER evaluation [24] all compared one-time gene therapy with common care (or the…”
Walters, M. C., Tisdale, J. F., Mapara, M. Y., et al. (2021) · Blood · doi:10.1182/blood-2021-146905 · Cited by 3 · cited 1×
“The HGB-206 trial also studied the impact of lovo-cel on patient-reported HRQOL outcomes [17, 56].”
Self-citationUdeze, C., Xie, Y., Ogunsile, F. J., et al. (2023) · Value in Health · doi:10.1016/j.jval.2023.03.474 · Cited by 3 · cited 1×
“The breadth of SCD-related events and complications included in our analysis is comparable to other comprehensive analyses of gene therapies [22–25, 29] , and there is Our analysis, the MEASURE analysis [29], and the ICER evaluation [24] all compared one-time gene therapy with common care (or the…”
Value of a cure for sickle cell disease in reducing economic disparities
Graf, M., Tuly, R., Gallagher, M., Sullivan, J., & Jena, A. B. (2022) · American Journal of Hematology · doi:10.1002/ajh.26617 · Cited by 2 · cited 3×
“The model leveraged educational pathways research [63] to project that achieving VOE-CR would support educational and work productivity gains, resulting in higher annual earnings depending on the age at treatment.”
InfluentialSelf-citationBarcelos, G. T., Besser, M. W., O’Flaherty, E., et al. (2022) · Value in Health · doi:10.1016/j.jval.2022.09.2051 · Cited by 2 · cited 1×
“The model captured the HRQOL impacts of SCD on both patients (in both co-base-case perspectives) and their caregivers (in the co-base-case societal perspective only) in the form of utility values [64, 65].”
Paramore, C., Kong, A. M., Minegishi, S., et al. (2018) · Blood · doi:10.1182/blood-2018-99-118874 · Cited by 1
Self-citationPurser, M. F., GALLAGHER, M. P., Mladsi, D. M., et al. (2020) · Value in Health · doi:10.1016/j.jval.2020.08.098 · Cited by 1 · cited 1×
“…[30], this approach is best suited to reflect the heterogeneity of the SCD population, the comprehensive set of SCD-related events and complications potentially impacted by a gene therapy, and the time-dependent relationships between events, complications, and mortality in SCD [30, 33].”
Self-citationDong, O. M., Purser, M. F., Herring, W. L., et al. (2023) · Value in Health · doi:10.1016/j.jval.2023.03.611 · Cited by 1
Self-citation
Research works printed but not linked: 4
- bluebird bio. bluebird bio Announces FDA Priority Review of the Biologics License Application for lovotibeglogene autotemcel (lovo-cel) for patients with sickle cell disease (SCD) 12 years and older with a history of vaso-occlusive events. 2023. https://www.businesswire.com/news/home/20230621695509/en/. Accessed 30 Aug 2023.
- Beaudoin F, Thokala P, Nikitin D, Campbell J, Spackman E, McKenna A, et al. Gene therapies for sickle cell disease: effectiveness and value; draft evidence report. Institute for Clinical and Economic Review. 2023. https://icer.org/wp-content/uploads/2023/04/SCD_FOR-PUBLICATION.pdf. Accessed 2 Aug 2023.
- Institute for Clinical and Economic Review. 2020–2023 value assessment framework. 2020. https://icer-review.org/wp-content/uploads/2020/10/ICER_2020_2023_VAF_102220.pdf. Accessed 29 Oct 2020.
- Wenzl M, Chapman S. Performance-based managed entry agreements for new medicines in OECD countries and EU member states. 2019. https://www.oecd-ilibrary.org/content/paper/6e5e4c0f-en. Accessed 8 Feb 2024.
Cited by
Gene therapy for genetic diseases: challenges and future directions
Beibei, Q. I. E., Tuo, J., Chen, F., Ding, H., & Lyu, L. (2025) · MedComm · doi:10.1002/mco2.70091 · Cited by 45
Is allogeneic transplantation for sickle cell disease still relevant in the era of gene therapy?
Jones, R. J., Kassim, A. A., Brodsky, R. A., & DeBaun, M. R. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013693 · Cited by 18
Starlard‐Davenport, A., Palani, C. D., Zhu, X., & Pace, B. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094192 · Cited by 10
“In the meantime, extraordinary progress was made by pharma companies in 2023 with the US FDA approval of the first two gene therapies for SCD, Casgevy (exagam-glogene autotemcel) [32,33] and Lyfgenia (lovotibeglogene autotemcel) [34,35].”
Zemplenyi, A. T., Leonard, J., Wright, G. C., DiStefano, M. J., Nair, K. V., Anderson, K. E., & McQueen, R. B. (2025) · PharmacoEconomics · doi:10.1007/s40273-025-01474-3 · Cited by 8
Kabrah, S. M. (2025) · Journal of Blood Medicine · doi:10.2147/jbm.s556513 · Cited by 12
Metadata
- Authors
- Herring, W. L., Gallagher, M. E., Shah, N., Morse, K., Mladsi, D., Dong, O. M., Chawla, A., Leiding, J. W., Zhang, L., Paramore, C., & Andemariam, B.
- Affiliations
- Karolinska Institutet (SE)
- Bluebird Bio (United States) (US)
- Duke University (US)
- Columbia University (US)
- RTI Health Solutions (US)
- UConn Health (US)
- Corresponding author
- Herring, William L.
- ORCID
- Venue
- PharmacoEconomics
- Published
- 2024-04-29
- Volume
- 42
- Issue
- 6
- Pages
- 693-714
- ISSN
- 1170-7690 (ISSN-L)
- 1179-2027
- PMC
- PMC11126463
- OpenAlex
- W4396212871
- Cited by
- 18
- References
- 65
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 1
- FWCI
- 5.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- PharmacoEconomics (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- bluebird bio
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- sickle cell disease, gene therapy, cost-effectiveness, vaso-occlusive events, autologous stem cell transplantation, quality-adjusted life years, life expectancy, societal perspective, third-party payer perspective, caregiver burden, indirect costs, United States health care system
- MeSH terms
- Adolescent, Adult, Anemia, Sickle Cell, Child, Cost-Benefit Analysis, Female, Humans, Male, Middle Aged, Quality of Life, Recurrence, United States, Genetic Therapy, Hematopoietic Stem Cell Transplantation, Models, Economic, Quality-Adjusted Life Years, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.